Trade KalVista Pharmaceuticals, Inc. - KALV CFD

Trading Conditions

• Spread: 0.07
• Long position overnight feeLong position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position-0.026179 %(-US$1.05)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: -0.026179%
• Short position overnight feeShort position overnight feeMargin. Your investmentUS$1,000.00Overnight feeCharges from full value of position0.003957 %(US$0.16)Trade size with leverage ~ US$5,000.00Short position overnight fee ~ US$4,000.00Go to platform: 0.003957%
• Overnight fee time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20
• Stock exchange: United States of America
• Commission on trade: 0%

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: -0.026179 %
  (-US$1.05)

• Margin. Your investment: US$1,000.00
• Overnight feeCharges from full value of position: 0.003957 %
  (US$0.16)

Key Stats

• Prev. Close: 10.31
• Open: 10.09
• 1-Year Change: 26.44%
• Day's Range: 10.09 - 10.35

KalVista Pharmaceuticals, Inc. Company profile

About Kalvista Pharmaceuticals Inc

KalVista Pharmaceuticals, Inc. is a clinical stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of small molecule protease inhibitors for diseases with unmet need. The Company has developed a portfolio of small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME). Plasma kallikrein is a serine protease enzyme, which is an early mediator of inflammation and edema. The body modulates the inflammatory effects of plasma kallikrein through a circulating inhibitor protein called C1-esterase inhibitor (C1-INH). The Company is primary focused on the development of the oral plasma kallikrein inhibitors for HAE. It has two drug program candidates in clinical trials. The Company’s DME program is focused on the development of an intravitreally administered small molecule plasma kallikrein inhibitor, KVD001, which completed a Phase II trial.

Financial summary

BRIEF: For the nine months ended 31 January 2022, Kalvista Pharmaceuticals Inc revenues was not reported. Net loss increased 86% to $58.2M. Higher net loss reflects Research and development increase of 73% to $51M (expense), General and administrative increase of 80% to $18.8M (expense), foriegn exchange gain/loss decrease from $715K (income) to $529K (expense). Basic Earnings per Share excluding Extraordinary Items decreased from -$1.75 to -$2.38.